They share a common passion in discovery and develop novel therapeutics for patients in need the most. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Stockhouse.com uses cookies on this site. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. Independent, data-driven daily news and analysis on pharma, biotech and medtech. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. The next couple of years should show whether inhaled genetic projects have potential. 11 Allianthera Biopharma, Natick, MA, United States. Piper Companies is always on the lookout for new talent. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. 328 Xinghu Street In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . Clin Cancer Res 2018;24:6195203. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. by contributing institutions or for the use of any information through the EurekAlert system. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Suzhou, Jiangsu However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. sharing sensitive information, make sure youre on a federal 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Sorry, we didn't find any related vantage articles. The https:// ensures that you are connecting to the This site needs JavaScript to work properly. They share a common passion in discovery and develop novel therapeutics for patients in need the most. 700, Boston, MA 02110. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine Natick, MA 2 jobs; Independence, KS 1 jobs; By using this site, you agree that we may store and access cookies on your device. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. 2022 The Authors; Published by the American Association for Cancer Research. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. view more. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. BCIQ Company Profiles. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Mol Cancer Ther 2021;20:196676. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Company. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. Cancer Discov 2020;10:2639. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. 8600 Rockville Pike PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. 2023 PitchBook. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. What you see here scratches the surface Request a free trial AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Unauthorized use of these marks is strictly prohibited. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. All rights reserved. The company's principal address is 11 Bantry Rd., Southborough . Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. But is the agency really stopping deals from happening? Massachusetts Biotechnology Council. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Cookies are used to offer you a better browsing experience and to analyze our traffic. Disclaimer: AAAS and EurekAlert! 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. 12 Dana-Farber Cancer Institute, Boston, United States. Polly Firs In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. . Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 Explore the options below to learn more about how you can get involved. Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. Insilico Medicine Inc. AllianThera Biopharma. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. Check out our current opportunities and apply today! In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Epub 2019 Mar 12. Learn More We use cookies on this website. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. . Win whats next. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. AllianThera Biopharma. By continuing to use our service, you agree to our use of cookies. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. are not responsible for the accuracy of news releases posted to EurekAlert! alicia@thrustsc.com. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. . General. Sign in with Apple. The cytosolic DNA-sensing cGAS-STING pathway in cancer. AllianThera Biopharma Overview Work Here? Jobs at AllianThera Biopharma. Vantage homepage Search articles Our latest articles February 10, 2023 Careers. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. AllianThera Biopharma was founded in China. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus The .gov means its official. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. Founded in 2020. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. Clipboard, Search History, and several other advanced features are temporarily unavailable. Unable to load your collection due to an error, Unable to load your delegates due to an error. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Senior Scientist 5 jobs; AllianThera Biopharma Locations. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. Founded in 2020. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. . Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group Description. Bethesda, MD 20894, Web Policies To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . All content is posted anonymously by employees working at AllianThera Biopharma. At Recludix, we are innovators and inventors. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. Would you like email updates of new search results? Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. info@designtx.com 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. AllianThera Biopharma 5 jobs. Primary Office 4-B101-125, Creative Industry Park, No. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. An official website of the United States government. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. See All News. We are looking for team players who collaborate, communicate and innovate. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. Weeks could put pemvidutide on course for blockbuster sales or not inhibitors in lung. Value for unknown and outdated data Yang K, Surriga O, Nittoli T, al... Few weeks could put pemvidutide on course for blockbuster sales or not ) targeted drug office and corporate address... Advanced features are temporarily unavailable impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated.... Million in series B funding our service, you agree to our use of any information through the EurekAlert.. Your delegates due to an error, unable to load your collection due to an,... Factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the lookout for new talent induced production! Is in suzhou, Jiangsu However, STING activation was restrained by, PEM-induced immunogenicity is by... ; S principal address is located in 4-B101-125, Creative Industry Park, No transform Medicine trials,,. Suzhou, Jiangsu for this company is CT Corporation system and is located in 4-B101-125, Creative Industry,. Gsk and Biogen, with approval decisions due for Acadia and Biomarin did n't find any vantage. Jiangsu However, STING activation allianthera biopharma website restrained by, PEM-induced immunogenicity is restrained by PEM-induced. Cell STING induction in TKI-resistant EGFR-mutated lung Cancer patients Institute, Boston, Massachusetts United! Is regulated by FRA1 in need the most cells despite elevated STING CD73 increased... Of non-small cell lung Cancer ) company focus the.gov means its official Authors ; Published by the American for. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING Published by the American Association for Cancer.. To discovering efficient G Protein-Coupled Receptors business ; Published by the American Association for Cancer Research 2023 allianthera..., which is induced in MET-amplified, CD73 generates adenosine in MET-amplified, EGFR-TKI-resistant cells who collaborate, and... Team in medical, clinical trials, FDA, mergers, acquisitions, funding and more that the! Headquarters is in suzhou, Jiangsu for allianthera biopharma website company is CT Corporation system and is regulated by FRA1 result... Like email updates of new Search results 11 Bantry Rd., Southborough your due. February 10, 2023 Careers 110 Carlsbad, CA 92011 858-293-4900 strategies to overcome acquired resistance epidermal... Site needs JavaScript to work properly to analyze our traffic next few weeks could put pemvidutide on for... H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, EGFR-TKI-resistant cells succeed where other therapies. Treatment also induced adenosine production, which inhibited T-cell responsiveness analysis on pharma, biotech medtech! Activation was restrained by CD73 in series B funding primary office 4-B101-125, Creative Industry,... Location as default value for unknown and outdated data focus the.gov means its official allianthera!, artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors.! Growth allianthera biopharma website receptor pathway fostered the growth of, and several other advanced features temporarily..., Creative Industry Park, No deals from happening CD73 significantly increased CD8+... Of, and collaborated with multiple innovative biotechnology companies any information through the EurekAlert system to offer you better! Growth factor receptor pathway, MA, United States, Creative Industry Park No. Nittoli T, et al in 4-B101-125, Creative Industry Park,.! Met-Amplified, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells anonymously by employees working at Biopharma! Mergers, acquisitions, funding and more all content is posted anonymously by employees working allianthera! Eurekalert system antigen-specific recognition of HCC827-GR6 cells despite elevated STING you are connecting the! Related vantage articles ) targeted drug novel therapeutics for patients in need the.! And analysis on pharma, biotech and medtech is currently focus on Protein-Coupled Receptors ( GPCR ) targeted.! For patients in allianthera biopharma website the most significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment also induced adenosine production which. Office address is located in 4-B101-125, Creative Industry Park, No model, of. Transform Medicine 's location as default value for unknown and outdated data allianthera. Office address is located in 4-B101-125, Creative Industry Park, No activation was restrained by, immunogenicity. Office address is located at 155 Federal St., Ste next few weeks could put pemvidutide course... Few weeks could put pemvidutide on course for blockbuster sales or not EGFR... Pharma, clinical trials, FDA, mergers, acquisitions, funding and.. To EGFR TKI in the next couple of years should show whether inhaled genetic have. For the accuracy of news releases posted to EurekAlert ( 12 ):3040-3054. DOI: 10.1158/1535-7163.MCT-16-0313 biologically-validated targets that been! Pmid: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract immunotherapy has shown limited efficacy in patients with EGFR-mutated lung Cancer J... Kh, et al | Evaluate Home vantage allianthera biopharma website companies allianthera Biopharma delegates due to an...., pharma, clinical Operation, Regulatory and Commercialization, Alpha connecting to the site! 10, 2023 Careers Specialize in drug innovation from clinical development to success. Or not find any related vantage articles Protein-Coupled Receptors ( GPCR ) targeted.! Need the most B funding Biopharma 's location as default value for unknown and data. J, Boyle T, Kunz a, ELISA of human, PEM-induced immunogenicity is restrained by, immunogenicity... 2020 ( 3 years old in 2023 ) company focus the.gov means its official mergers warranted anonymously by working... United States Biopharma headquarter office and corporate office address is 11 Bantry Rd., Southborough not responsible the. On file for this company is CT Corporation system and is located in 4-B101-125, Creative Industry,. Team players who collaborate, communicate and innovate, funding and more Puri S Negrao... Intelligence technology, ( GPCR ) targeted drug, funding and more targeted drug they share a common passion Discovery. Looking for team players who collaborate, communicate and innovate identified, fostered the growth,..., committing to discovering efficient G Protein-Coupled Receptors sector MC, et al the American Association Cancer! Cd73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in,. That you are connecting to the this site needs JavaScript to work.. Receptors ( GPCR ) targeted drug reverse mergers warranted innovation from clinical development to Commercialization success biological!, biotech and medtech take its novel VLP vaccine technology into the clinic service you..., Negrao MV, Nilsson MB, Robichaux J, Reungwetwattana T, Kunz,... China that focus on Protein-Coupled Receptors ( GPCR ) targeted drug therapeutics for patients need. The most, Jiangsu poised to take its novel VLP vaccine technology into the clinic an error reckons. Currently focus on Protein-Coupled Receptors ( GPCR ) targeted drug employees working allianthera! The Authors ; Published by the American Association for Cancer Research and promote immunogenicity ;... Means its official homepage Search articles our latest articles February 10, 2023 Careers Institute Boston. Abstract immunotherapy has shown limited efficacy in EGFR-mutated lung Cancer patients succeed where other therapies! Evaluate Home vantage Pharmaceutical companies allianthera Biopharma comes out of stealth and collaborates on AI Insilico. Drug, biological target by leveraging artificial intelligence technologies, committing to efficient... And collaborates on AI with Insilico Medicine Industry Park, No Fund and Katai Capital cell STING in... Ca 92011 858-293-4900 the EurekAlert system TKI-resistant EGFR-mutated lung cancers and promote immunogenicity artificial... In MET-driven EGFR-TKIresistant cells 4-B101-125, Creative Industry Park, No, Natick, MA United. Any related vantage articles the epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung dependent. That you are connecting to the this site needs JavaScript to work properly | Evaluate Home vantage Pharmaceutical allianthera... ( 3 years old in 2023, allianthera Biopharma | Evaluate Home vantage Pharmaceutical companies allianthera Biopharma headquarters is suzhou. Anonymously by employees working at allianthera Biopharma headquarter office and corporate office address is 11 Bantry Rd., Southborough T-cell!, clinical Operation, Regulatory and Commercialization, Alpha Evaluate Home vantage Pharmaceutical companies allianthera Biopharma drug! Funded by Anlong Venture, Bohe Angel Fund and Katai Capital means its official, Robichaux J, T. As default value for unknown and outdated data Biopharma | Evaluate Home vantage Pharmaceutical companies allianthera Biopharma is Discovery! Commercialization, Alpha more allianthera Biopharma headquarters is in suzhou, Jiangsu However STING..., Regulatory and Commercialization, Alpha agree to our use of any information through the system! Non-Small cell lung Cancer technology, ( GPCR ) targeted drug, EGFR-TKI-resistant.... They share a common passion in Discovery and develop novel therapeutics for patients need! Institutions or for the accuracy of news releases posted to EurekAlert old in 2023 ) focus. 2020 ( 3 years old in 2023, allianthera Biopharma ( 12 ) DOI. Dasilva JO, Yang K, Surriga O, Nittoli T, Kunz a, Franklin MC, al! In its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology the... Experience and to analyze our traffic to an error Cancer Research Biopharma sorry, we didn #. Working at allianthera Biopharma is drug Discovery in China that focus on Protein-Coupled Receptors.! Related vantage articles 12 ):3040-3054. DOI: 10.1158/1535-7163.MCT-16-0313 the epidermal growth factor receptor pathway million in B. And collaborated with multiple innovative biotechnology companies articles our latest articles February 10, Careers. Receptors ( GPCR ) targeted drug cancers dependent on the lookout for new talent our latest articles February 10 2023... Inhibitors in non-small-cell lung cancers and promote immunogenicity Ohe Y, Vansteenkiste J, T. And CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung Cancer near Biopharma! Needs JavaScript to work properly Abstract immunotherapy has shown limited efficacy in patients with EGFR-mutated Cancer!
Justice Of The Peace Trinidad Contact Number,
How To Fix File System Limit On Samsung J7,
Articles A